PLCG2 and mantle cell lymphoma: Similarly, BTK plus PLCγ2 mutations, including mutations in the BTK amino acids L528, A428, and V416, were discovered in REC-1 mantle cell lymphoma (MCL) cell lines, which are resistant to vecabrutinib, pirtobrutinib, and fenebrutinib.